GF Fund Management
ADPT icon

GF Fund Management’s Adaptive Biotechnologies ADPT Stock Holding History

GF Fund Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$103K Buy
3,549
+289
+9% +$7.1K ﹤0.01% 335
2026
Q2 		$69.9K Sell
3,260
-170
-5% -$2.6K ﹤0.01% 360
2026
Q1 		$47.6K Buy
3,430
+432
+14% +$6.88K ﹤0.01% 407
2025
Q4 		$48.7K Sell
2,998
-278
-8% -$4.54K ﹤0.01% 408
2025
Q3 		$49K Sell
3,276
-503
-13% -$6.13K ﹤0.01% 397
2025
Q2 		$44K Hold
3,779
– – ﹤0.01% 429
2025
Q1 		$28.1K Buy
3,779
+680
+22% +$5.23K ﹤0.01% 467
2024
Q4 		$18.6K Buy
+3,099
New +$17.1K ﹤0.01% 478

Other funds holding ADPT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Granite Investment Partners
Granite Investment Partners El Segundo, California $1.84B AUM 35.93% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Capricorn Fund Managers
Capricorn Fund Managers London, United Kingdom $1.06B AUM 45.98% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

GF Fund Management's ADPT Position: Q3 2026 in Review

GF Fund Management increased its Adaptive Biotechnologies (ADPT) stake by 8.9% in Q3 2026, buying an estimated $7.1K and bringing the position to 3,549 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #335.

GF Fund Management first reported a position in ADPT in Q4 2024 and has held it in 8 quarters since. 116 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

  • GF Fund Management held 3,549 shares of Adaptive Biotechnologies worth $103K as of Q3 2026.
  • GF Fund Management bought 289 Adaptive Biotechnologies shares in Q3 2026, an estimated $7.1K.
  • Adaptive Biotechnologies made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #335 holding.
  • GF Fund Management first reported a position in Adaptive Biotechnologies in Q4 2024 and has held it in 8 quarters since.
  • 116 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.